Torren Management’s Atrium Therapeutics RNA Stock Holding History

Torren Management’s Portfolio RNA Stock Details RNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$54	Hold	4	–	–	﹤0.01%	930
2026 Q1	$53	Buy	+4	New	+$56	﹤0.01%	962

Other funds holding RNA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return

TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return

CIEC

Crédit Industriel et Commercial Paris France, France $1.55B AUM 42.08% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

YIH

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

MWM

Moran Wealth Management Naples, Florida $3.67B AUM 36.71% 1-Year Est. Return

Fractal Investments Glastonbury, Connecticut $867M AUM 23.63% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Torren Management's RNA Position: Q2 2026 in Review

Torren Management held its Atrium Therapeutics (RNA) position steady in Q2 2026 at 4 shares worth $54. The position accounts for ﹤0.01% of the portfolio, ranked #930.

Torren Management first reported a position in RNA in Q1 2026 and has held it in 2 quarters since. 47 funds tracked by Wall St. Rank hold RNA as of Q2 2026.

Torren Management held 4 shares of Atrium Therapeutics worth $54 as of Q2 2026.
Torren Management left its Atrium Therapeutics share count unchanged in Q2 2026.
Atrium Therapeutics made up ﹤0.01% of Torren Management's portfolio in Q2 2026, its #930 holding.
Torren Management first reported a position in Atrium Therapeutics in Q1 2026 and has held it in 2 quarters since.
47 funds tracked by Wall St. Rank held Atrium Therapeutics as of Q2 2026.

Based on Torren Management's 13F filing for Q2 2026, filed 10 Jul 2026.